Related Experiment Video
Updated: Sep 17, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Dose-response relationship between aspirin and gastric cancer risk: A systematic review and meta-analysis
Shan Zhang1, Hongwei Wang1, Jingjing Ji1
1Department of Epidemiology and Biostatistics, School of Public Health of Jilin University, Changchun 130021, China.
Abstract:
Gastric cancer (GC) continues to be a significant global health burden, ranking as the fifth most prevalent malignancy and the fourth leading cause of cancer-related mortality worldwide. Emerging evidence suggests that aspirin, a well-known cyclooxygenase (COX) inhibitor, may play a role in reducing the risk of gastric cancer. However, the dose-response relationship between aspirin use and gastric cancer risk remains unclear. This systematic review and meta-analysis aimed to elucidate this relationship by analyzing data from cohort studies published between January 1, 2014, and January 1, 2024. A comprehensive search of PubMed, Embase, and Web of Science yielded six eligible studies involving over 1.5 million participants. The results demonstrated a significant inverse association between aspirin dose and gastric cancer risk, with a relative risk (RR) of 0.73 (95 % CI: 0.57-0.94) for the highest versus lowest aspirin dose. Dose-response analysis revealed a nonlinear relationship, suggesting that higher doses of aspirin were associated with a greater reduction in gastric cancer risk. Subgroup analyses suggested regional variations in the protective effect of aspirin, with stronger associations observed in Asian populations. Our results provide strong evidence of the association between dose of aspirin use and risk of gastric cancer. These findings highlight the potential role of aspirin in gastric cancer chemoprevention and offer valuable insights for future research and clinical applications.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Dose-Response Relationship: Overview
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

